MCID: HYP014
MIFTS: 55

Hyperuricemia

Categories: Metabolic diseases, Blood diseases, Rare diseases

Aliases & Classifications for Hyperuricemia

MalaCards integrated aliases for Hyperuricemia:

Name: Hyperuricemia 12 76 55 44 15 73
Blood Urate Raized 12
Uricacidemia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1920
MeSH 44 D033461
NCIt 50 C3961
UMLS 73 C0740394

Summaries for Hyperuricemia

Disease Ontology : 12 An acquired metabolic disease that has material basis in an abnormally high level of uric acid in the blood.

MalaCards based summary : Hyperuricemia, also known as blood urate raized, is related to hyperuricemic nephropathy, familial juvenile, 1 and nephrolithiasis, uric acid, and has symptoms including cachexia, cyanosis and dyspnea. An important gene associated with Hyperuricemia is UMOD (Uromodulin), and among its related pathways/superpathways are Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds and Folate Metabolism. The drugs Allopurinol and Furosemide have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and endothelial, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 76 Hyperuricemia is an abnormally high level of uric acid in the blood. In the pH conditions of body fluid,... more...

Related Diseases for Hyperuricemia

Diseases in the Hyperuricemia family:

Hereditary Hyperuricemia

Diseases related to Hyperuricemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 141)
# Related Disease Score Top Affiliating Genes
1 hyperuricemic nephropathy, familial juvenile, 1 33.5 HPRT1 SLC22A12 UMOD
2 nephrolithiasis, uric acid 30.4 HPRT1 XDH
3 chronic kidney failure 29.9 CRP INS REN UMOD
4 kidney disease 29.7 CRP INS REN UMOD
5 interstitial nephritis 29.4 CRP REN UMOD
6 coronary heart disease 1 28.8 APOB CRP INS
7 ischemic heart disease 28.6 APOB CRP INS
8 gout 28.5 ABCG2 HPRT1 SLC17A1 SLC17A3 SLC22A12 SLC2A9
9 arteries, anomalies of 28.1 APOB CRP INS REN
10 arteriosclerosis 28.0 APOB CRP INS
11 diabetes mellitus, noninsulin-dependent 27.7 ADRB3 APOB CRP G6PC INS
12 hypertension, essential 27.7 ADRB3 APOB CRP INS REN
13 diabetes mellitus 27.5 ADRB3 APOB CRP INS REN
14 vascular disease 27.2 APOB CRP INS REN XDH
15 hyperuricemia, pulmonary hypertension, renal failure, and alkalosis syndrome 12.3
16 glomerulocystic kidney disease with hyperuricemia and isosthenuria 12.2
17 hereditary hyperuricemia 12.0
18 deafness hyperuricemia neurologic ataxia 11.9
19 hyperuricemia, infantile, with abnormal behavior and normal hypoxanthine guanine phosphoribosyltransferase 11.8
20 nephropathy familial with hyperuricemia 11.8
21 lesch-nyhan syndrome 11.8
22 hyperuricemic nephropathy, familial juvenile, 2 11.5
23 autosomal dominant tubulointerstitial kidney disease 11.5
24 kelley-seegmiller syndrome 11.5
25 fructose intolerance, hereditary 11.1
26 glycogen storage disease ia 11.1
27 glycogen storage disease ib 11.0
28 autosomal dominant tubulointerstitial kidney disease, ren-related 10.8
29 uric acid concentration, serum, quantitative trait locus 1 10.8
30 urate oxidase, pseudogene 10.8
31 glycogen storage disease ic 10.8
32 phosphoribosylpyrophosphate synthetase superactivity 10.8
33 hyperuricemic nephropathy, familial juvenile, 4 10.8
34 familial primary hypomagnesemia with hypercalciuria and nephrocalcinosis 10.8
35 postural hypotension 10.5 INS REN
36 purine-pyrimidine metabolic disorder 10.5 HPRT1 XDH
37 hypouricemia, renal, 1 10.4 HPRT1 SLC22A12 SLC2A9
38 fanconi-bickel syndrome 10.4 G6PC INS
39 adenine phosphoribosyltransferase deficiency 10.3 HPRT1 XDH
40 malignant otitis externa 10.2 CRP INS
41 endotheliitis 10.2
42 epidural abscess 10.1 CRP SLC2A9
43 aging 10.1
44 fatty liver disease 10.1
45 abdominal obesity-metabolic syndrome quantitative trait locus 2 10.1 CRP INS
46 arthritis 10.0
47 liver disease 10.0
48 nonalcoholic fatty liver disease 10.0
49 heart disease 10.0
50 xanthinuria 10.0 HPRT1 SLC22A12 SLC2A9 XDH

Graphical network of the top 20 diseases related to Hyperuricemia:



Diseases related to Hyperuricemia

Symptoms & Phenotypes for Hyperuricemia

UMLS symptoms related to Hyperuricemia:


cachexia, cyanosis, dyspnea, edema, fever, headache, icterus, seizures, signs and symptoms, signs and symptoms, digestive, syncope, vertigo, polydipsia, muscle weakness, hot flushes

MGI Mouse Phenotypes related to Hyperuricemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.1 ABCG2 ADRB3 G6PC HPRT1 INS PFKM
2 homeostasis/metabolism MP:0005376 10.07 ADRB3 APOB CRP G6PC HPRT1 INS
3 growth/size/body region MP:0005378 10.02 ADRB3 APOB G6PC HPRT1 INS REN
4 cardiovascular system MP:0005385 9.97 HPRT1 INS PFKM REN SLC22A12 SLC2A9
5 adipose tissue MP:0005375 9.91 ABCG2 ADRB3 INS SLC2A9 UMOD XDH
6 immune system MP:0005387 9.85 REN SLC2A9 UMOD XDH ABCG2 APOB
7 liver/biliary system MP:0005370 9.43 ABCG2 APOB G6PC HPRT1 INS SLC2A9
8 renal/urinary system MP:0005367 9.28 ABCG2 G6PC HPRT1 INS REN SLC22A12

Drugs & Therapeutics for Hyperuricemia

Drugs for Hyperuricemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 162)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Allopurinol Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 315-30-0 2094
2
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
3
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
4
Rasburicase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 134774-45-1
5
Febuxostat Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 144060-53-7 134018
6
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 53-03-2 5865
7
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
8
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
9
Probenecid Approved, Investigational Phase 4,Phase 2 57-66-9 4911
10
Colchicine Approved Phase 4,Phase 2 64-86-8 6167 2833
11
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
12
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
13
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 44475014
14
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
15
Canagliflozin Approved Phase 4 842133-18-0
16
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 59-30-3 6037
17
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
18
leucovorin Approved, Nutraceutical Phase 4 58-05-9 143 6006
19
Methylcobalamin Approved, Experimental, Investigational, Nutraceutical Phase 4 13422-55-4
20
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
21
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
22
Uric Acid Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 69-93-2 1175
23 Anti-Infective Agents Phase 4,Phase 3
24 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25 Antioxidants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Antiparasitic Agents Phase 4
27 Antiprotozoal Agents Phase 4
28 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Not Applicable
31 diuretics Phase 4,Phase 3
32 Natriuretic Agents Phase 4,Phase 3
33 Sodium Chloride Symporter Inhibitors Phase 4,Phase 3
34 Sodium Potassium Chloride Symporter Inhibitors Phase 4
35 insulin Phase 4,Phase 3,Not Applicable
36 Insulin, Globin Zinc Phase 4,Phase 3,Not Applicable
37 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3
38 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3
39 glucocorticoids Phase 4,Phase 2,Phase 3
40 Hormone Antagonists Phase 4,Phase 2,Phase 3
41 Hormones Phase 4,Phase 2,Phase 3
42 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3
43 Renal Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
44 Angiotensin II Type 1 Receptor Blockers Phase 4
45 Angiotensin Receptor Antagonists Phase 4
46 Angiotensinogen Phase 4
47
Olmesartan medoxomil Phase 4 144689-63-4 130881
48 Antimitotic Agents Phase 4,Phase 2
49 Diacetylrhein Phase 4
50 Analgesics Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 156)
# Name Status NCT ID Phase Drugs
1 Investigation of the Atherogenic Effects of Uric Acid-modified in Endothelial Dysfunction and the the Preventional Mechanism by Anthocyanidines Unknown status NCT02797028 Phase 4 Allopurinol
2 Clinical Trial to Compare Effectiveness of Diuretics in Hemodialysis Patients With Residual Renal Function Unknown status NCT01977430 Phase 4 Hydrochlorothiazide and furosemide
3 Prednisone for Heart Failure Patients With Hyperuricemia Completed NCT00919243 Phase 4 prednisone;allopurinol
4 Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome Completed NCT00563771 Phase 4 Rasburicase
5 Zurig (Febuxostat) 40mg Efficacy and Safety Trial Completed NCT02600780 Phase 4 Febuxostat;Allopurinol
6 Rasburicase in Tumor Lysis Syndrome Completed NCT00302653 Phase 4 Rasburicase
7 Treatment of Hyperuricemia in Patients With Heart Failure Completed NCT00422318 Phase 4 Benzbromarone (drug)
8 Effects of Hyperuricemia Reversal on Features of the Metabolic Syndrome Completed NCT01654276 Phase 4 Febuxostat
9 Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy Completed NCT00230217 Phase 4 Rasburicase (SR29142)
10 Allopurinol in Chronic Heart Failure Completed NCT00997542 Phase 4 Allopurinol;Placebo
11 Drug Interaction Study of Olmesartan in Healthy Chinese Volunteers Completed NCT01907373 Phase 4 olmesartan medoxomil;olmesartan medoxomil+probenecid
12 Allopurinol Outcome Study Completed NCT01391325 Phase 4 Allopurinol
13 Weight Loss Improves Renal Hemodynamics Completed NCT01356394 Phase 4
14 Fasturtec TLS Treatment / Prophylysis Completed NCT00651911 Phase 4 urate oxidase
15 Immune Molecular and Inflammatory Cytokines Dysfunction Analysis in Gout Patients With Different Urate Levels Completed NCT02060552 Phase 4 Diacerein;Colchicine;Febuxostat
16 Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout Completed NCT02500641 Phase 4 Febuxostat 80/120mg/day;Allopurinol 100 up to 600mg/day;Colchicine;Naproxen;Omeprazole
17 Lowering-hyperuricemia Treatment on Cardiovascular Outcomes in Peritoneal Dialysis Patients Recruiting NCT03200210 Phase 4 Febuxostat;Placebo
18 Effect of Hyperuricaemia on Chronic Renal Disease Recruiting NCT03425708 Phase 4 20mg Febuxostat;40mg Febuxostat
19 The Intervention of Multi-vitamin With Minerals to Hyperuricemia Recruiting NCT03218709 Phase 4
20 The Impact of Urate-lowering Therapy on Kidney Function (IMPULsKF) Recruiting NCT03336203 Phase 4 Febuxostat 80 MG Oral Tablet or Allopurinol 300 MG Oral Tablet
21 The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics Active, not recruiting NCT02956278 Phase 4 Allopurinol
22 Pharmacogenetics of SGLT2 Inhibitors Enrolling by invitation NCT02462421 Phase 4 Canagliflozin
23 Urate Lowering Therapies and Left Ventricular Diastolic Dysfunction Not yet recruiting NCT03534037 Phase 4 Febuxostat 40 mg;Benzbromarone 50mg
24 the Effect of Febuxostat on Coronary Plaque Volume in Patients With Chronic Stable Angina and Hyperuricemia Terminated NCT02279342 Phase 4 Febuxostat
25 Role of Allopurinol on Oxidative Stress and Mitochondrial Alterations in Skeletal Muscle of Diabetic Patients Unknown status NCT02533648 Phase 3 2 capsules of allopurinol 150 mg daily for 3 month;2 capsules of lactose daily for 3 month
26 Safety and Efficacy of TULY (Rasburicase) in Prevention and Treatment of Malignancy-associated Hyperuricemia Completed NCT00921375 Phase 3 TULY
27 Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome Completed NCT00230178 Phase 3 Rasburicase (SR29142);Allopurinol
28 Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma Completed NCT00199043 Phase 3 Allopurinol;Rasburicase
29 Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout Completed NCT00325195 Phase 3
30 Efficacy and Safety of Oral Febuxostat in Participants With Gout Completed NCT00430248 Phase 3 Febuxostat;Febuxostat;Allopurinol
31 Uric Acid and Hypertension in African Americans Completed NCT00241839 Phase 3 Allopurinol;Placebo;Chlorthalidone;Potassium chloride
32 Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout Completed NCT01356498 Phase 3
33 Molecular and Clinical Effects of Green Tea and Fermented Papaya Preparation on Diabetes and Cardiovascular Diseases Completed NCT01248143 Phase 2, Phase 3
34 Effect of Febuxostat on Endothelial Dysfunction in Hemodialysis Patients. Completed NCT02866214 Phase 2, Phase 3 Febuxostat;Placebo
35 Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010 Completed NCT00175019 Phase 3 Febuxostat;Febuxostat;Allopurinol
36 Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES) Completed NCT01101035 Phase 3 Febuxostat;Allopurinol
37 BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada Completed NCT00272779 Phase 3 ATV;RTV;Tenofovi-Emtricitabine (TDF/FTC) tablet;LPV
38 Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer Completed NCT01234337 Phase 3 Sorafenib (Nexavar, BAY43-9006);Placebo;Capecitabine
39 Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout Recruiting NCT03372200 Phase 3 FYU-981;Febuxostat
40 Prednisone for Heart Failure Patients With Hyperuricemia Recruiting NCT02129764 Phase 2, Phase 3 Prednisone;Allopurinol
41 Long-term Prednisone Use for End-stage Heart Failure Recruiting NCT02282683 Phase 2, Phase 3 prednisone
42 UAB Center of Research Translation (CORT) Project 2: The Effects of Urate Lowing Therapy (ULT) in Inflammation, Endothelial Function, and Blood Pressure Recruiting NCT02038179 Phase 2, Phase 3 Allopurinol;Placebo
43 The Effects of Doxazosin and Nifedipine on Blood Pressure Variability and Uric Acid in Plasma in Hypertensive Patients Recruiting NCT02563405 Phase 2, Phase 3 Doxazosin;Nifedipine
44 Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout Active, not recruiting NCT03100318 Phase 3 FYU-981;Benzbromarone
45 Study of FYU-981 in Hyperuricemia With or Without Gout Active, not recruiting NCT03006445 Phase 3 FYU-981
46 Rasburicase (Fasturtec) Registration Trial Terminated NCT00607152 Phase 3 Rasburicase;Allopurinol
47 Study of Levotofisopam 50 mg Three Times a Day (TID) Administered for 7 Days on Hyperuricemia and Gout Unknown status NCT01519687 Phase 2 levotofisopam
48 A Clinical Double Blind, Randomized Study of the Efficacy of Hyperuricemia Treatment With Anserine Product. Unknown status NCT00208000 Phase 2 Marine active
49 Hyperuricemia on Hypertension and Metabolic Syndrome Completed NCT01157936 Phase 2 Allopurinol
50 Genetics of Hyperuricemia Therapy in Hmong Completed NCT02371421 Phase 2 Allopurinol

Search NIH Clinical Center for Hyperuricemia

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: hyperuricemia

Genetic Tests for Hyperuricemia

Anatomical Context for Hyperuricemia

MalaCards organs/tissues related to Hyperuricemia:

41
Kidney, Heart, Endothelial, Liver, Lung, Skeletal Muscle, Bone

Publications for Hyperuricemia

Articles related to Hyperuricemia:

(show top 50) (show all 758)
# Title Authors Year
1
Renal Effects of Hyperuricemia. ( 29393089 )
2018
2
Identification of new drug-like compounds from millets as Xanthine oxidoreductase inhibitors for treatment of Hyperuricemia: A molecular docking and simulation study. ( 29906649 )
2018
3
Treatment of Hyperuricemia in Chronic Kidney Disease. ( 29393124 )
2018
4
Hyperuricemia and Progression of Chronic Kidney Disease: Role of Phenotype Transition of Renal Tubular and Endothelial Cells. ( 29393109 )
2018
5
Hypouricemic Effects of Extracts From <i>Agrocybe aegerita</i> on Hyperuricemia Mice and Virtual Prediction of Bioactives by Molecular Docking. ( 29867500 )
2018
6
Value of three-dimensional speckle tracking echocardiography to assess left ventricular function in hyperuricemia patients. ( 29790109 )
2018
7
Significance of Hyperuricemia among Community-Based Screening Participants. ( 29393126 )
2018
8
Prevalence of hyperuricemia and its associated factors in the general Korean population: an analysis of a population-based nationally representative sample. ( 29790110 )
2018
9
Management of hyperuricemia and gout in obese patients undergoing bariatric surgery. ( 29888674 )
2018
10
Lesinurad/Allopurinol (Duzallo) for Gout-Associated Hyperuricemia. ( 29318274 )
2018
11
Inhibiting PNP for the therapy of hyperuricemia in Lesch-Nyhan disease: preliminary in vitro studies with analogues of immucillin-G. ( 29869162 )
2018
12
Reduced peak stimulated growth hormone is associated with hyperuricemia in obese children and adolescents. ( 29785038 )
2018
13
Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan. ( 29363262 )
2018
14
Impact of hyperuricemia on clinical outcomes after percutaneous coronary intervention for in-stent restenosis. ( 29890945 )
2018
15
Cordycepin, a Characteristic Bioactive Constituent in<i>Cordyceps militaris</i>, Ameliorates Hyperuricemia through URAT1 in Hyperuricemic Mice. ( 29422889 )
2018
16
Dietary Potential Renal Acid Load Is Positively Associated with Serum Uric Acid and Odds of Hyperuricemia in the German Adult Population. ( 29378039 )
2018
17
Systemic Implications of Hyperuricemia. ( 29393131 )
2018
18
White blood cell count and the incidence of hyperuricemia: insights from a community-based study. ( 29936636 )
2018
19
What is the role of angiotensin receptor blockers in treatment of hyperuricemia coexisting with arterial hypertension? ( 29853726 )
2018
20
Identification of four genes as novel susceptibility loci for early-onset type 2 diabetes mellitus, metabolic syndrome, or hyperuricemia. ( 29930802 )
2018
21
Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions for disease elements in gout. ( 29799677 )
2018
22
Associations of hyperuricemia and obesity with remission of nonalcoholic fatty liver disease among Chinese men: A retrospective cohort study. ( 29415050 )
2018
23
Hyperuricemia enhances intracellular urate accumulation via down-regulation of cell-surface BCRP/ABCG2 expression in vascular endothelial cells. ( 29317200 )
2018
24
Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study). ( 29372470 )
2018
25
Genetic association and functional analysis of rs7903456 in FAM35A gene and hyperuricemia: a population based study. ( 29942023 )
2018
26
The effects of xanthine oxidase inhibitor in patients with chronic heart failure complicated with hyperuricemia: a prospective randomized controlled clinical trial of topiroxostat vs allopurinol-study protocol. ( 29916098 )
2018
27
Physiology of Hyperuricemia and Urate-Lowering Treatments. ( 29904633 )
2018
28
Metabolomics approach by <sup>1</sup>H NMR spectroscopy of serum reveals progression axes for asymptomatic hyperuricemia and gout. ( 29871692 )
2018
29
Identification of CDC42BPG as a novel susceptibility locus for hyperuricemia in a Japanese population. ( 29124443 )
2018
30
Hyperuricemia in Asian psoriatic arthritis patients. ( 29349920 )
2018
31
Hyperuricemia as a prognostic factor after acute coronary syndrome. ( 29407598 )
2018
32
Markers of Iron Status Are Associated with Risk of Hyperuricemia among Chinese Adults: Nationwide Population-Based Study. ( 29425155 )
2018
33
Compounds containing trace element copper or zinc exhibit as potent hyperuricemia inhibitors via xanthine oxidase inactivation. ( 29895374 )
2018
34
Rhabdomyolysis following status epilepticus with hyperuricemia: A case report and literature review. ( 29953009 )
2018
35
Hyperuricemia is associated with short-term outcomes in elderly patients with acute myocardial infarction. ( 29411328 )
2018
36
Tamm-Horsfall Protein/Uromodulin Deficiency Elicits Tubular Compensatory Responses Leading to Hypertension and Hyperuricemia. ( 29357410 )
2018
37
Mangiferin alleviates hypertension induced by hyperuricemia via increasing nitric oxide releases. ( 29934052 )
2018
38
Heat Stress Nephropathy and Hyperuricemia. ( 29897286 )
2018
39
Hyperuricemia does not seem to be an independent risk factor for coronary heart disease. ( 28917080 )
2017
40
(E)-2-(4-bromophenyl)-1-(2, 4-dihydroxyphenyl)ethanone oxime is a potential therapeutic agent for treatment of hyperuricemia through its dual inhibitory effects on XOD and URAT1. ( 27951420 )
2017
41
Impact of Hyperuricemia on Long-term Outcomes of Kidney Transplantation: Analysis of the FAVORIT Study. ( 28801121 )
2017
42
Gender difference on the relationship between hyperuricemia and nonalcoholic fatty liver disease among Chinese: An observational study. ( 28953666 )
2017
43
Assessment of subclinical left ventricular changes in essential hypertensive patients with hyperuricemia: A three-dimensional speckle-tracking echocardiography study. ( 28072551 )
2017
44
The association of hyperuricemia and metabolic syndrome in Thai postmenopausal women. ( 28937289 )
2017
45
Chicken or the Egg? Hyperuricemia, Insulin Resistance, and Hypertension. ( 28808070 )
2017
46
Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN). ( 28794514 )
2017
47
The role of hyperuricemia on vascular endothelium dysfunction. ( 28928970 )
2017
48
Development of Nephrolithiasis in Asymptomatic Hyperuricemia: A Cohort Study. ( 28410765 )
2017
49
The prevalence, subtypes and associated factors of hyperuricemia in lupus nephritis patients at chronic kidney disease stages 1-3. ( 28915657 )
2017
50
The management of hyperuricemia: back to the pathophysiology of uric acid. ( 28952386 )
2017

Variations for Hyperuricemia

Expression for Hyperuricemia

Search GEO for disease gene expression data for Hyperuricemia.

Pathways for Hyperuricemia

Pathways related to Hyperuricemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.86 ABCG2 G6PC SLC17A1 SLC17A3 SLC22A12 SLC2A9
2
Show member pathways
11.59 APOB CRP INS XDH
3 10.59 HPRT1 XDH
4 10.1 ABCG2 SLC17A1 SLC17A3 SLC22A12 SLC2A9

GO Terms for Hyperuricemia

Cellular components related to Hyperuricemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 apical plasma membrane GO:0016324 9.17 ABCG2 PFKM SLC17A1 SLC17A3 SLC22A12 SLC2A9
2 endosome lumen GO:0031904 8.96 APOB INS

Biological processes related to Hyperuricemia according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 transmembrane transport GO:0055085 9.8 ABCG2 SLC17A1 SLC17A3 SLC22A12 SLC2A9
2 glucose homeostasis GO:0042593 9.61 G6PC INS PFKM
3 response to organic substance GO:0010033 9.54 APOB INS REN
4 anion transport GO:0006820 9.52 SLC17A1 SLC17A3
5 organic anion transport GO:0015711 9.51 SLC17A3 SLC22A12
6 drug transmembrane transport GO:0006855 9.49 ABCG2 SLC17A3
7 cholesterol efflux GO:0033344 9.48 ABCG2 APOB
8 glycogen catabolic process GO:0005980 9.46 G6PC PFKM
9 phosphate ion transport GO:0006817 9.32 SLC17A1 SLC17A3
10 negative regulation of blood vessel diameter GO:0097756 9.26 CRP INS
11 urate transport GO:0015747 9.26 SLC17A1 SLC17A3 SLC22A12 SLC2A9
12 glucose-6-phosphate transport GO:0015760 9.16 G6PC SLC17A3
13 urate metabolic process GO:0046415 9.1 ABCG2 G6PC SLC17A1 SLC17A3 SLC22A12 SLC2A9

Molecular functions related to Hyperuricemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.8 ABCG2 ADRB3 HPRT1 PFKM XDH
2 low-density lipoprotein particle receptor binding GO:0050750 9.37 APOB CRP
3 cholesterol transporter activity GO:0017127 9.32 ABCG2 APOB
4 insulin-like growth factor receptor binding GO:0005159 9.26 INS REN
5 transmembrane transporter activity GO:0022857 9.26 SLC17A1 SLC17A3 SLC22A12 SLC2A9
6 sodium:phosphate symporter activity GO:0005436 9.16 SLC17A1 SLC17A3
7 urate transmembrane transporter activity GO:0015143 8.8 SLC17A3 SLC22A12 SLC2A9

Sources for Hyperuricemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....